Glyceryl 1-phosphate,(R)- or glycerol-3-phosphate is a precursor for fatty acid esterification into triglycerides. Esterification of fatty acids to triglycerides in peripheral tissues such as skeletal muscle and adipose tissue is dependent on the synthesis of glycerol-3-phosphate from glucose. Triacylglycerols (TAG) serve as the predominant form of energy storage in mammalian cells, and TAG synthesis influences conditions such as obesity, fatty liver, and insulin resistance. Human skeletal muscle glycerol-3-phosphate, lactate was decreased after the high-fat diets.

AMPHETAMINE TARTRATE at doses of less than 5 mg/kg tartrate cause hyperphagia and weight gain of castrated rats. It was available in France until 1971 as restricted prescription drug Corydrane.

Piperidine is a normal constituent in mammalian brain. It was shown to affect synaptic mechanism in the CNS, and influence neural mechanisms governing regulation of emotional behavior, sleeping, and extrapyramidal function. In addition, there are enzyme systems within the brain that synthesize and metabolize piperidine, and uptake and storage mechanisms for piperidine are found in the nerve endings. Piperidine, which proved to be a highly effective “antipsychotomimetic” agent in rats, has been reported to bring about substantial improvement in a variety of schizophrenic patients.

AMPROTROPINE (Syntropan) is the phosphate salt of 3 diethylamine, 2.2 dimethylpropanol tropic acid ester. Syntropan is antispasmodic. Its main effect is parasympathetic, and its internal uses are chiefly the same as those of atropine. Syntropan produces relaxation of the tone of the stomach and inhibition of peristaltic activity. The effect of syntropan on gastric secretion excited by a meat extract meal and histamine is weak as compared with atropine. Its advantages as a mydriatic were also described: the rapid effect; the short duration; no general dangers nor discomforts; no local dangers, as damaging the corneal epithelium, or increasing the intraocular pressure; no delay in returning to work for the patient.

Thiabendazole (TBZ, trade names Mintezol, Tresaderm, and Arbotect) was first introduced in 1962. This drug is a fungicide and parasiticide and is indicated for the treatment of: strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, trichinosis: relief of symptoms and fever and a reduction of eosinophilia have followed the use of this drug during the invasion stage of the disease. But usage of this drug was discontinued. The precise mode of action of thiabendazole on the parasite is unknown, but it may inhibit the helminthspecific enzyme fumarate reductase. It was shown, also that thiabendazole reversibly disassembles newly established blood vessels, marking it as vascular disrupting agent (VDA) and thus as a potential complementary therapeutic for use in combination with current anti-angiogenic therapies. Was shown, that vascular disruption by TBZ results from reduced tubulin levels and hyper-active Rho signaling. In addition, was confirmed, that thiabendazole slowed tumor growth and decreased vascular density in preclinical fibrosarcoma xenografts and thus, it could lead directly to the identification of a potential new therapeutic application for an inexpensive drug that is already approved for clinical use in humans.